Valeo Pharma Inc.
VPH.TO
TSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.20M | 10.41M | 10.03M | 9.65M | 10.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.20M | 10.41M | 10.03M | 9.65M | 10.56M |
| Cost of Revenue | 6.69M | 8.28M | 8.36M | 8.08M | 7.81M |
| Gross Profit | 2.51M | 2.13M | 1.67M | 1.58M | 2.75M |
| SG&A Expenses | 3.40M | 5.00M | 5.27M | 5.38M | 5.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.09M | 13.28M | 13.63M | 13.46M | 13.13M |
| Operating Income | -891.00K | -2.87M | -3.60M | -3.81M | -2.57M |
| Income Before Tax | -5.98M | -5.76M | -5.09M | -6.81M | -4.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.98M | -5.76M | -5.09M | -6.81M | -4.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.98M | -5.76M | -5.09M | -6.81M | -4.38M |
| EBIT | -891.00K | -2.87M | -3.60M | -3.81M | -2.57M |
| EBITDA | -452.80K | -2.42M | -3.19M | -3.35M | -2.12M |
| EPS Basic | -0.06 | -0.06 | -0.06 | -0.07 | -0.05 |
| Normalized Basic EPS | -0.02 | -0.04 | -0.04 | -0.04 | -0.03 |
| EPS Diluted | -0.06 | -0.06 | -0.06 | -0.07 | -0.05 |
| Normalized Diluted EPS | -0.02 | -0.04 | -0.04 | -0.04 | -0.03 |
| Average Basic Shares Outstanding | 98.68M | 98.68M | 86.14M | 93.16M | 84.47M |
| Average Diluted Shares Outstanding | 98.68M | 98.68M | 86.14M | 93.16M | 84.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
